Evidence map›Paper›PMID 25193961›Full record

ArticleHaematologica2014

The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.

Yuan-Yeh Kuo, Hsin-An Hou, Yin-Kai Chen, Li-Yu Li, Po-Hsuen Chen, Mei-Hsuan Tseng, Chi-Fei Huang, Fen-Yu Lee, Ming-Chih Liu, Chia-Wen Liu and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yuan-Yeh KuoGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei; yykuo@ntu.edu.tw.
Hsin-An HouGraduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Yin-Kai ChenDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Li-Yu LiGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei;
Po-Hsuen ChenGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei;
Mei-Hsuan TsengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Chi-Fei HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Fen-Yu LeeDepartment of Pathology, National Taiwan University Hospital, Taipei;
Ming-Chih LiuDepartment of Pathology, National Taiwan University Hospital, Taipei;
Chia-Wen LiuDepartment of Pathology, National Taiwan University Hospital, Taipei;
Wen-Chien ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei;
Chieh-Yu LiuBiostatistics Consulting Laboratory, Department of Nursing, National Taipei College of Nursing, Taiwan.
Jih-Luh TangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Ming YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei;
National Taiwan University Hospital · TWNational Taiwan University · TWNational Taipei University of Nursing and Health Science · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXC chemokine receptor 4 (CXCR4) is an essential regulator for homing and maintenance of hematopoietic stem cells within the bone marrow niches. Analysis of clinical implications of bone marrow CXCR4 expression in patients with acute myeloid leukemia showed not only higher CXCR4 expression was an independent poor prognostic factor, irrespective of age, white blood cell counts, cytogenetics, and mutation status of NPM1/FLT3-ITD and CEBPA, but also showed CXCR4 expression was inversely associated with mutations of CEBPA, a gene encoding transcription factor C/EBPα. Patients with wild-type CEBPA had significantly higher CXCR4 expression than those with mutated CEBPA. We hypothesized that CEBPA might influence the expression of CXCR4. To test this hypothesis, we first examined endogenous CXCR4 expression in 293T and K562 cells over-expressing wild-type C/EBPα p42 and demonstrated that CXCR4 levels were increased in these cells, whilst the expression of the N-terminal mutant, C/EBPα p30, diminished CXCR4 transcription. We further showed p42 was bound to the CXCR4 promoter by the chromatin immunoprecipitation assays. Induction of p42 in the inducible K562-C/EBPα cell lines increased the chemotactic migration. Moreover, decreased expression of C/EBPα by RNA interference decreased levels of CXCR4 protein expression in U937 cells, thereby abrogating CXCR4-mediated chemotaxis. Our results provide, for the first time, evidence that C/EBPα indeed regulates the activation of CXCR4, which is critical for the homing and engraftment of acute myeloid leukemia cells, while p30 mutant impairs CXCR4 expression.

Indexed as

Gene Expression Regulation, NeoplasticAdolescentAdultAgedAged, 80 and overBlotting, WesternBone MarrowCase-Control StudiesCCAAT-Enhancer-Binding ProteinsChemotaxisCohort StudiesFemaleFlow CytometryFollow-Up StudiesHematopoietic Stem CellsHumansCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanCXCR4 protein, humanNPM1 protein, humanNucleophosminReceptors, CXCR4RNA, MessengerRNA, Small Interfering

Identifiers

PMID25193961
PMCPMC4258761
OpenAlexW2105974034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.